Recombinant human growth hormone treatment. Its effect on renal allograft function and histology.
Our objective was to investigate the effects of recombinant human growth hormone (rhGH) treatment on long-term renal allograft function and histopathology. RhGH is a potent therapy for poor growth after renal transplantation. However, rhGH has proinflammatory properties and may induce acute rejection or accelerate chronic rejection. Nine prepubertal rhGH-treated renal transplanted children and nine pair-matched controls were studied 18 (before the start of rhGH) and 36 months after transplantation (mean duration of rhGH-treatment 14 months). 51Cr-EDTA- and PAH-clearances were performed. A protocol renal biopsy was done at 36 months. Growth showed significant improvement during rhGH (P<0.01). One graft loss occurred in both groups. One acute rejection was seen in the control group. There was no difference in the rate pf change in 51Cr-EDTA-or PAH-clearance between the two groups. Histopathological findings were mostly mild. One new onset chronic rejection developed in both groups. Proximal tubular atrophy was more extensive in the rhGH-treated patients (P<0.05), but there was no uniform trend toward more severe findings. RhGH improved growth, and no significant differences were seen in allograft function or histopathology; however, larger trials controlled for pretreatment renal function and immunosuppression are needed.
Laine
J
J
Children's Hospital and Transplantation Laboratory, University of Helsinki, Finland.
Krogerus
L
L
Sarna
S
S
Jalanko
H
H
Rönnholm
K
K
Holmberg
C
C
D000208:Acute Disease; D002648:Child; D002657:Child Development / Q000187:drug effects; D002675:Child, Preschool; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival / Q000187:drug effects; D006128:Growth / Q000187:drug effects; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007668:Kidney / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D013006:Growth Hormone